Business Wire

SAMSUNG-ELECTRONICS

Share
Samsung Electronics Announces Successful Building of Industry-First CXL Infrastructure Certified by Red Hat

Samsung Electronics Co., Ltd., the world leader in advanced memory technology, today announced that for the first time in the industry, it has successfully built a Compute Express Link™ (CXL™) infrastructure certified by Red Hat, the world’s leading provider of open source solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625016573/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Samsung Electronics Announces Successful Building of Industry-First CXL Infrastructure Certified by Red Hat (Photo: Business Wire)

Elements that configure servers, from CXL-related products to software, can now be directly verified at the Samsung Memory Research Center (SMRC) located in Hwaseong, South Korea. Once CXL products are verified by Samsung, they can immediately be requested for product registration to Red Hat, enabling faster product development.

Marking its first achievement through the infrastructure, Samsung has successfully verified its CMM-D product for the first time in industry this month. The company can also provide tailored solutions to customers by optimizing products at earlier development stages.

“We’re very pleased that our partnership with Red Hat is able to deliver CXL memory products with enhanced reliability to our customers,” said Taeksang Song, Vice President and Head of the New DRAM Solution Development Team at Samsung Electronics. “Through our continued collaboration spanning software and hardware, we will remain at the forefront of developing innovative memory solutions as well as the CXL ecosystem.”

Kyeong Sang Kim, Red Hat Korea GM said, “The optimization of Samsung’s hardware for Red Hat’s software underscores the value of open source technology as an imperative when it comes to expanding next generation memory solutions such as CMM-D. We look forward to continuing our collaboration with Samsung to further extend CXL solutions to the market.”

Following the successful CXL memory verification by Red Hat for the first time in the industry last December, Samsung has also been certified for datacenter SSD products. Customers using Red Hat-certified products can build high-performance systems by receiving world-class Linux support, complementing the stable hardware operation of Samsung.

Samsung and Red Hat have also been working closely together in various areas, including product certification for both hardware and software, enriching the next-generation CXL ecosystem.

At the Red Hat Summit held in Denver, Colorado, in May, Samsung demonstrated its CMM-D1 embedded in Red Hat Enterprise Linux 9.3, which enhances the performance of Deep Learning Recommendation Models (DLRM).

The demo utilized the Scalable Memory Development Kit's (SMDK) Memory Interleaving software technology, highlighting improved memory access performance. SMDK-equipped CMM-D allows customers to build high-performance AI models, without having to make significant investments, by accelerating the data processing, AI learning and inferencing speeds.

Through their strong partnership, Samsung and Red Hat aim to provide customer solutions suitable for a wide range of user systems while introducing new technology standards to an array of partners and customers and expanding the CXL memory ecosystem.

1 CMM-D is Samsung’s CXL Memory Module DRAM, a DRAM solution based on the PCIe interface that supports the CXL protocol.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, home appliances, network systems, and memory, system LSI, foundry and LED solutions, and delivering a seamless connected experience through its SmartThings ecosystem and open collaboration with partners. For the latest news, please visit the Samsung Newsroom at news.samsung.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240625016573/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye